Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVL-231 as IR formulation · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 10 mg CVL-231 as IR formulation | DRUG | Tablets |
| 30 mg CVL-231 as slow-release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 as medium release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 as fast release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 Target Release, Fasted | DRUG | Capsules |
| 30 mg CVL-231 Target Release, Fed | DRUG | Capsules |
Top 15 of 16 competitors
CVL-231 as IR formulation is an immediate-release oral small molecule that AbbVie Inc. is developing for schizophrenia. It is an investigational Phase 1 asset and has not been approved for any use. The immediate-release version is distinct from other formulations of CVL-231 studied in clinical development.
CVL-231 as IR formulation is being studied for schizophrenia, a psychiatric disorder. The clinical work to date has focused on how the drug behaves in the body rather than on treating patients, since the program remains in Phase 1 development. No approved indication exists for this formulation.
AbbVie Inc. (ticker ABBV) is the developer of CVL-231 as IR formulation. The company holds the program for this immediate-release oral small molecule, which is being evaluated in schizophrenia. AbbVie is the sponsor of the registered clinical trial for this formulation.
CVL-231 as IR formulation is in Phase 1 development. It is an investigational drug and is not FDA approved. The single registered trial for this formulation has been completed, and no active trials for it are currently listed.
CVL-231 as IR formulation has been studied in one completed Phase 1 trial, NCT05106309. That trial examined the pharmacokinetics of CVL-231 after single oral doses of modified-release and immediate-release formulations in fasted and fed healthy participants, and it enrolled 16 participants. The study was uncontrolled and is now complete.